Skip to main content
Log in

Study of hydroxyproline excretion in patients with prostatic cancer

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Urinary hydroxyproline concentrations were measured in 36 prostatic cancer patients. Metastases were ruled out by radiography in 24, and confirmed in 12 cases. 14 patients with no malignant disease served as controls. In patients with no metastases excretion was similar to that in the controls, in some of them it was higher. In the patients with higher values the studies were repeated six months later: deposits were found in all cases but one. In the group in which deposits had been present at the outset the values of the untreated patients were significantly higher than in the controls, whereas in the treated patients no consistent values were found.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Basu, T. K., Donasocon, D., Williams, D.: Urinary hydroxyproline and plasma mucoprotein as an indication of the presence of bone metastasis.Oncology, 30, 197 (1974).

    PubMed  Google Scholar 

  2. Basu, T. K., Raven, R. W., Dickerson, J. W. T., Williams, D. C.: Leucocyte ascorbic acid and urinary hydroxyproline levels in patients bearing breast cancer with skeletal metastases.Eur. J. Cancer, 10, 507 (1974).

    PubMed  Google Scholar 

  3. Bishop, M. C., Fellows, G. J.: Urine hydroxyproline excretion — a marker of bone metastases in prostatic cancer.Brit. J. Urol., 49, 711 (1977).

    PubMed  Google Scholar 

  4. Cuschieri, C. S. B.: Urinary hydroxyproline excretion in early and advanced breast cancer — a sequential study.Brit. J. Surg., 60, 800 (1973).

    PubMed  Google Scholar 

  5. Galasko, C. B. S.: Problems associated with the detection of skeletal metastases.J. Roy. Soc. Med., 71, 38 (1978).

    Google Scholar 

  6. Kolár, J., Vyhnánek, L., Bek, V., Babicky, A., Janko, L., Drápálovau, D.: Zur Diagnostik der Knochenmetastasen bei urologischen Krebskrankheiten mit radioaktiven Isotopen.Zschr. Urol., 8, 578 (1967).

    Google Scholar 

  7. Kontturi, M. J., Sotaniemi, E. A., Larmi, T. K. I.: Hydroxyproline in the early diagnosis of bone metastases in prostatic cancer.Scand. J. Urol., 8, 91 (1974).

    Google Scholar 

  8. Laitinen, O., Nikkilä, E. A., Kivirikko, K. I.: Hydroxyproline in the serum and urine.Acta med. scand., 179, 275 (1966).

    PubMed  Google Scholar 

  9. Neumann, R. E., Logan, M.: The determination of hydroxyproline.J. B. C., 184, 299 (1950).

    Google Scholar 

  10. Platt, W. D., Doolittle, L. H., Hartschorn, J. W. S.: Urine hydroxyproline excretion in metastatic cancer of the bone.New Engl. J. Med., 271, 267 (1964).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Romics, I., Budavári, I., Kisbenedek, L. et al. Study of hydroxyproline excretion in patients with prostatic cancer. International Urology and Nephrology 13, 275–278 (1981). https://doi.org/10.1007/BF02082425

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02082425

Keywords

Navigation